Gold prices steady ahead of Fed decision, Trump’s tariff deadline
ArsenalBio, based in South San Francisco, California, is focused on defeating cancer by developing a pipeline of autologous T cell therapies. Its clinical pipeline includes treatments for kidney cancer and preclinical candidates for prostate cancer and other solid tumors, in addition to the partnered programs with Bristol Myers Squibb. For investors interested in deep analysis of BMY's market position and growth potential, InvestingPro offers comprehensive research reports and additional insights, including 8 more key ProTips and detailed financial metrics that help evaluate the company's investment potential. For investors interested in deep analysis of BMY's market position and growth potential, InvestingPro offers comprehensive research reports and additional insights, including 8 more key ProTips and detailed financial metrics that help evaluate the company's investment potential.
ArsenalBio, based in South San Francisco, California, is focused on defeating cancer by developing a pipeline of autologous T cell therapies. Its clinical pipeline includes treatments for kidney cancer and preclinical candidates for prostate cancer and other solid tumors, in addition to the partnered programs with Bristol Myers Squibb. For investors interested in deep analysis of BMY's market position and growth potential, InvestingPro offers comprehensive research reports and additional insights, including 8 more key ProTips and detailed financial metrics that help evaluate the company's investment potential.
ArsenalBio's collaboration with Bristol Myers Squibb involves the discovery and preclinical development of candidates against multiple targets. Bristol Myers Squibb has the option to further develop and commercialize these candidates. With the exercise of the licensing option, Bristol Myers Squibb will take on the responsibility for the development and potential commercialization of the AB-4000 series.
Ken Drazan, M.D., Chairman and CEO of ArsenalBio, expressed confidence in the collaboration and the shared vision with Bristol Myers Squibb to transform the treatment of solid tumors through advanced cell engineering. He also highlighted the potential benefits for patients and the continued eligibility of ArsenalBio for additional milestone payments and royalties from the progress of these programs.
ArsenalBio, based in South San Francisco, California, is focused on defeating cancer by developing a pipeline of autologous T cell therapies. Its clinical pipeline includes treatments for kidney cancer and preclinical candidates for prostate cancer and other solid tumors, in addition to the partnered programs with Bristol Myers Squibb.
The information in this article is based on a press release statement from Arsenal Biosciences.
In other recent news, Bristol-Myers Squibb (NYSE:BMY) has been the subject of several analyst reports. Truist Securities maintained a Buy rating and raised their price target from $62.00 to $65.00. The firm predicts revenues of $47.4 billion for 2024, $45.7 billion for 2025, and $42.8 billion for 2026. They also anticipate robust sales performance of several products to persist into 2025.
Bristol-Myers Squibb has also reported successful outcomes from its Phase 3 trials of Sotyktu in treating active psoriatic arthritis. The company received approval from the European Commission for the use of Opdivo and Yervoy as a first-line treatment for certain types of colorectal cancer.
Piper Sandler released a report detailing their top biotechnology picks for 2025 within the Central Nervous System vertical. Meanwhile, TD Cowen raised concerns about the global pharmaceutical industry's future due to the impact of U.S. tariffs and geopolitical tensions. However, large-cap pharmaceutical companies, including Bristol-Myers Squibb, are seen as well-positioned to mitigate these risks. These are recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.